Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2426
NPK International
NPKI
$965M
| $1.27M | ﹤0.01% |
570,020
-236,141
| -29% | -$400K |
2017 Q3
11 quarters
|
|
|
FGH
2427
DELISTED
FG Group Holdings Inc.
FGH
| $1.27M | ﹤0.01% |
774,810
+145,290
| +23% | +$237K |
2013 Q2
28 quarters
|
|
|
CASA
2428
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $1.27M | ﹤0.01% |
+305,249
| New | +$1.29M |
2020 Q2
0 quarters
|
|
2429
Actinium Pharmaceuticals
ATNM
$33.3M
| $1.27M | ﹤0.01% |
120,212
+80,664
| +204% | +$611K |
2018 Q1
9 quarters
|
|
2430
Bio-Rad Laboratories Class B
BIO.B
| $1.27M | ﹤0.01% |
2,900
+900
| +45% | +$381K |
2016 Q4
14 quarters
|
|
|
GMDA
2431
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $1.26M | ﹤0.01% |
+276,300
| New | +$1.27M |
2020 Q2
0 quarters
|
|
|
RBNC
2432
DELISTED
Reliant Bancorp, Inc. Common Stock
RBNC
| $1.26M | ﹤0.01% |
77,425
+33,900
| +78% | +$453K |
2017 Q2
12 quarters
|
|
2433
Avalo Therapeutics
AVTX
$723M
| $1.26M | ﹤0.01% |
+168
| New | +$1.22M |
2020 Q2
0 quarters
|
|
2434
iShares Core S&P Total US Stock Market ETF
ITOT
$98B
| $1.26M | ﹤0.01% |
18,100
-9,600
| -35% | -$628K |
2019 Q4
2 quarters
|
|
2435
Vanguard Morningstar Small-Cap Growth ETF
VBK
$23.1B
| $1.26M | ﹤0.01% |
+6,300
| New | +$1.14M |
2020 Q2
0 quarters
|
|
2436
Vanguard Morningstar Mid-Cap Growth ETF
VOT
$19.7B
| $1.25M | ﹤0.01% |
+7,600
| New | +$1.15M |
2020 Q2
0 quarters
|
|
2437
Quince Therapeutics
QNCX
$32.3M
| $1.25M | ﹤0.01% |
135
+110
| +440% | +$1.01M |
2020 Q1
1 quarter
|
|
2438
PDS Biotechnology
PDSB
$105M
| $1.25M | ﹤0.01% |
622,672
+313,051
| +101% | +$349K |
2017 Q1
13 quarters
|
|
2439
SiTime
SITM
$17.3B
| $1.25M | ﹤0.01% |
+26,400
| New | +$784K |
2020 Q2
0 quarters
|
|
2440
Perma-Pipe International
PPIH
$258M
| $1.25M | ﹤0.01% |
222,394
+1,052
| +0.5% | +$6.08K |
2013 Q2
28 quarters
|
|
|
MSBF
2441
DELISTED
MSB Financial Corp.
MSBF
| $1.25M | ﹤0.01% |
110,150
-1,000
| -0.9% | -$11.8K |
2016 Q1
17 quarters
|
|
2442
Neuronetics
STIM
$160M
| $1.24M | ﹤0.01% |
642,318
+63,221
| +11% | +$130K |
2019 Q3
3 quarters
|
|
2443
Chicago Rivet & Machine Co
CVR
$9.81M
| $1.24M | ﹤0.01% |
59,510
-1,600
| -3% | -$33.4K |
2013 Q2
28 quarters
|
|
2444
Merchants Bancorp
MBIN
$2.27B
| $1.24M | ﹤0.01% |
100,425
-22,500
| -18% | -$238K |
2019 Q2
4 quarters
|
|
|
IEA
2445
DELISTED
Infrastructure and Energy Alternatives, Inc. Common Stock
IEA
| $1.24M | ﹤0.01% |
309,383
+76,450
| +33% | +$169K |
2018 Q2
8 quarters
|
|
2446
First Bank
FRBA
$437M
| $1.23M | ﹤0.01% |
189,295
-43,800
| -19% | -$310K |
2016 Q4
14 quarters
|
|
2447
DELISTED
Neenah, Inc. Common Stock
NP
| $1.23M | ﹤0.01% |
24,800
-5,675
| -19% | -$273K |
2019 Q3
3 quarters
|
|
|
ITCL
2448
DELISTED
Banco Itau Chile American Depositary Shares (each representing one third of one (1/3) Common Share)
ITCL
| $1.23M | ﹤0.01% |
318,066
-334
| -0.1% | -$1.34K |
2016 Q2
16 quarters
|
|
|
SCNI
2449
Scinai Immunotherapeutics
SCNI
$766K
| $1.22M | ﹤0.01% |
54
+33
| +157% | +$531K |
2019 Q4
2 quarters
|
|
2450
iShares Semiconductor ETF
SOXX
$45.3B
| $1.22M | ﹤0.01% |
+13,500
| New | +$1.09M |
2020 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.